Dare Bioscience, Inc. — Form S-1
Filed August 26, 2026 · analyzed by the Registration Agent
S-1
▲ Likely positive
significance 72/100
What the filing says
On August 14–17, 2026, Dare Bioscience completed a registered direct offering and concurrent private placement: issued 4,085,687 common shares and 293,894 pre-funded warrants at $1.37 per share (net proceeds ~$5.3M); issued Series A warrants (4,379,581 shares) and Series B warrants (4,379,581 shares) at $1.37 exercise price; issued placement agent warrants (175,183 shares) at $2.1235 exercise price. This S-1 registers resale of up to 8,934,345 shares issuable upon warrant exercise. Company is tiny ($21.3M market cap), facing Nasdaq delisting risk, and relies on warrant exercise cash to fund operations.
Why this rating
Fundraising of ~$5.3M is ~25% of market cap—material for survival. Warrant overhang of 8.9M shares (~45% dilution if exercised) is substantial risk. Nasdaq hearing outcome critical to continued trading.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.